HLA Antibodies in Systemic Lupus Erythematosus

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06921239

Acronym

LEDHLA

Enrollment

Registered

2025-04-10

Start date

2025-02-10

Completion date

2027-05-01

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HLA Antibodies, Systemic Lupus Erythematosus

Keywords

HLA antibodies, systemic lupus erythematosus

Brief summary

Patients suffering from autoimmune diseases show false-positive results when anti-HLA antibodies are identified. This false positivity makes it difficult to obtain an organ transplant based on immunological compatibility (absence of anti-HLA antibodies directed against graft antigens). The objectives of this project are to study the prevalence of these false positivities in a population of lupus patients, and to evaluate biological tests that can negate these false positivities.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients Adults * Followed in the internal medicine department of Amiens University Hospital - With systemic lupus erythematosus * Without HLA immunization risk factors (no history of pregnancy, transfusions or transplants) * With sera stored in the biobank

Exclusion criteria

* minor Patients * Opposing the re-use of their personal data for research purposes

Design outcomes

Primary

Measure	Time frame	Description
prevalence of unexplained antibody positivity	6 months	prevalence of unexplained antibody positivity

Countries

France

Contacts

CONTACTNicolas GUILLAUME, Pr

guillaume.nicolas@chu-amiens.fr33+322087046

Outcome results